More articles about Biomarker Discovery & Validation | GenomeWeb

More articles about Biomarker Discovery & Validation

The company's technology will be used to analyze samples from a large cohort of Chinese volunteers to identify biomarkers for early cancer detection.

Cancer Genetics will provide the services to support H3's development of H3B-8800, a Phase I small molecule-based blood cancer drug candidate.

The companies will use Guardant's liquid biopsy assay to select patients with a biomarker for a clinical trial of an anti-RSP03 compound OncoMed is developing. 

The company has developed a panel of 15 genes, identified from scientific literature, that specifically link to an athlete's potential to respond to power or endurance training.  

The European Commission recently awarded the researchers €1.5 million to probe the mechanics of heart failure using proteomic, genomic, and epidemiological approaches.

The companies will collaborate to identify personalized aging-related biomarkers based on individuals' age-annotated genomic and transcriptomic data.

Caris Life Sciences also found that time-to-next treatment could be a surrogate endpoint for survival.

The university formed the new venture in collaboration with Blueprint Bio and Emerald Logic in order to discover biomarkers for personalized medicine.

Researchers will develop PCR and next-generation sequencing assays for aberrantly methylated vimentin, with the goal of commercializing a screening test. 

The NIH aims to fund projects studying the potential of exosomes and their cargo as biomarkers for cancer risk assessment, detection, diagnosis, and prognosis.

The company is using its MIRA assay internally and in research collaborations to identify biomarkers that can serve as the basis for immunotherapies. 

CeMeT, short for Center for Metagenomics, was founded in 2014 as a spinout from genetic diagnostics firm CeGaT in Tübingen.

The startup  will use the fund to begin commercialization of its PCR-based VerifyDx prostate cancer test.  

The arrangement builds on a previous collaboration around the development and validation of the company's SeptiCyte host-response assay for sepsis diagnosis.

Principia will use Guardant's liquid biopsy assay to monitor the response of patients in a clinical trial of its FGFR inhibitor. 

The company's Avatar platform cultures and propagates a variety of cell types in an in vivo-like environment to yield more accurate and relevant molecular analyses.

The funding will be used to establish labs that will discover and develop new biomarkers, or refine existing ones, for early cancer detection.

An analysis of samples taken a year after kidney transplant identified overlapping gene expression signatures associated with acute and chronic rejection.

The team said their approach may have several applications, including evaluation of cellular response to therapies, and early diagnosis of diseases like cancer.

The NIH has also set aside about $5.8 million in fiscal 2016 funding to support biomarker research and to set up a coordinating center for the consortium.


In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.